IMPACT OF THREE DIFFERENT GLYCOPROTEIN IIb/IIIa ANTAGONISTS ON GLYCOPROTEIN IIb/IIIa PLATELET RECEPTOR INHIBITION, TISSUE LEVEL PERFUSION AND CLINICAL ENDPOINTS in PATIENTS WITH ACUTE CORONARY SYNDROMES OR ANTIPLATELET RESISTANCE

Trial Profile

IMPACT OF THREE DIFFERENT GLYCOPROTEIN IIb/IIIa ANTAGONISTS ON GLYCOPROTEIN IIb/IIIa PLATELET RECEPTOR INHIBITION, TISSUE LEVEL PERFUSION AND CLINICAL ENDPOINTS in PATIENTS WITH ACUTE CORONARY SYNDROMES OR ANTIPLATELET RESISTANCE

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Abciximab (Primary) ; Eptifibatide (Primary) ; Tirofiban (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms POTS
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 31 Jul 2009 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
    • 15 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top